Startup profile · funding coverage
David (Medici Brands) funding, valuation and investors
Consumer nutrition brand owned by Medici Brands; its parent raised $250 million at a $2.25 billion valuation in September 2026.
Keep track of David (Medici Brands)
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B (Medici Brands)
$250M · September 2, 2026
Latest known valuation
$2.25B
Series B (Medici Brands) · September 2, 2026
Total disclosed equity funding
$250M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth
Investors in latest funding
Lead: Greenoaks , Valor Equity Partners
Other: ICONIQ , Imaginary Ventures
Overview
David is a high-protein food brand operated under Medici Brands. On September 2, 2026 Medici Brands announced a $250 million Series B co-led by Greenoaks and Valor Equity Partners. CEO Peter Rahal told Inc. the parent company was valued at $2.25 billion. The financing applies to Medici Brands, not to David as a separately priced legal entity.
Why David (Medici Brands) is interesting
David has large consumer brand search demand, while valuation and funding queries remain low difficulty; the parent-company structure is easy for generic funding databases to misstate.
Key facts
- Sep 2, 2026: Medici Brands raised $250M Series B
- Parent valuation: $2.25B
- David is one of Medici Brands' consumer brands
Funding history (newest first)
Series B (Medici Brands)
2026-09-02 $250M Valuation: $2.25B- Greenoaks (lead)
- Valor Equity Partners (lead)
- ICONIQ (participant)
- Imaginary Ventures (participant)
Market / IPO context
Note: Medici Brands valuation of $2.25B disclosed with the September 2026 Series B; do not present this as a separately priced David-only valuation.
Editorial / static context — not a live quote.
FAQs about David (Medici Brands)
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.